DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acne Vulgaris

Intervention: Isotretinoin: Reference Medication 1 (Drug); Isotretinoin: Reference Medication 2 (Drug); Isotretinoin: Test Medication (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline


This is an open-label, crossover, randomized, single dose, three treatments, three periods and six sequences, single dosage, balanced study to determine Bioequivalence of Isotretinoin. Bioequivalence will be compared between the reference medication one (T1) vs the test medication (T3): (T1 vs T3); and the reference medication two (T2), vs test medication (T3): (T2 vs T3). Finally, treatments T1 vs T2 will be compared statistically to determine if they are bioequivalent.

Clinical Details

Official title: Bioequivalence Study for an Isotretinoin Pharmaceutical Preparation - Capsules. Open, Crossover, Randomized, Single Dose, Three Treatments, Three Periods and Six Sequences With Meal (Breakfast) Study

Study design: Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Area under the plasma concentration-time curve from zero hours to last quantifiable time (AUC0-t)

Area under the plasma concentration-time curve from zero hours to infinite (AUC0-infinity)

Maximum drug concentration (Cmax)

Time to maximum drug concentration (Tmax)


Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Male.


Inclusion Criteria:

- Included in study will be male volunteers.

- Ages between 18 and 45 years old.

- BMI (Body Mass Index) between 20 to 26 kilogram/meter square (kg/m^2).

- Anti-doping tests negative results.

- Negative test results for Ac human immunodeficiency virus (HIV), HBsAg (hepatitis B

surface antigen), and rapid plasma regain (RPR; syphilis test).

- Clinical biochemical test values: Hematic Biometry, Urine Analysis, Biochemical

Profile: (Glucose, Ureic Nitrogen, Urea, Creatinine, Uric Acid, Cholesterol, Triglycerides, Total Proteins, Albumin, Globulin, Bilirubin (total, indirect and direct), Alkaline Phosphatase (ALP), Lactic Dehydrogenase, Asparate aminotransferase (AST), Alanine aminotransferase (ALT), Calcium, Phosphorus, Sodium, Potassium, Chlorine and Iron), Ac HIV, HBsAg and RPR, must fall within an interval between minimum and maximum values in connection to said tests accepted values.

- Normal Electrocardiogram (ECG) and Chest X-rays.

- Complete the scale 'Columbia Suicide Severity Rating Scale' (C-SSRS), before and

after each dosification period.

- Obtain a grade of zero in the C-SSRS.

- Signed the Informed Consent corresponding to the bioequivalence study.

- In exception cases, accepted may be a candidate for which any previously mentioned

test is exceeded regarding considered valid maximum and minimum accepted normal values, as long as it involves an isolated value and there are no other manifestations which could allow assuming that a given value is related to a disease or is remnant of another. These cases must be approved by clinical area and declared as "Non-clinically significant". Exclusion Criteria:

- Electrocardiographic Anomalies; radiological

- Anti-doping tests positive results,

- Positive results regarding RPR; HIV and HBsAg tests.

- Personal or family history of allergy to medication in question.

- Having any kind of allergy, since these persons are in higher risk of suffering from

medication allergy.

- Tobacco use.

- Persons undergoing any medical treatment.

- Existence of concurrent or intercurrent disease.

- History psychiatric disorder (eg, Major Depressive Disorder, Generalized Anxiety

Disorder, Bipolar Disorder (I or II), or schizophrenia).

- Existence of justified doubt regarding questionnaire answers truthfulness.

- Having participated in bioequivalence or bioavailability studies or having donated

blood 2 months before the study.

- Presence of clinically important gastrointestinal diseases or malabsorption history

during the last year.

- Presence of a medical condition requiring regular medication (with prescription or

over-the- counter medication) with systemic absorption.

- Drugs or alcohol addiction history requiring treatment.

- Refuse to take the scale 'C-SSRS, before and after each dosification period.

- Obtain a grade greater than zero in the C-SSRS.

- Do not sign the Informed Consent corresponding to the bioequivalence study.

- Finally, excluded will be all those volunteers not meeting that established in

Mexican Official Standard NOM-177-SSA1-1998.

Locations and Contacts

GSK Investigational Site, Monterrey, Nuevo León 64600, Mexico
Additional Information

Starting date: May 2013
Last updated: July 13, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017